【TMCLIFE 0101 交流专区】TMC生命科学

icy97

icy97 发表于 26-7-2017 11:57 PM
http://www.bursamalaysia.com/market/listed-companies/company-announcements/5496873

Type	Announcement
Subject	OTHERS
Description	UPDATE ON PROPOSED ACQUISITION OF SASTERIA PTE LTD BY ROWSLEY LIMITED
Further to announcement dated 26 July 2017 in respect of the Proposed Acquisition of entire issued and paid-up share capital of Sasteria Pte Ltd by Rowsley Limited (“Rowsley”) (“Proposed Acquisition”), the Board of Directors of TMC Life Sciences Berhad (“the Company” or “TMCLS”) wishes to update that:- Rowsley has entered into an agreement with Mr Lim Eng Hock on 18 December 2017 in relation to the said Proposed Acquisition (“Acquisition Agreement”). Rowsley has on 19 December 2017 obtained a ruling under Section 217(4) of the Capital Markets and Services Act 2007 from the Securities Commission of Malaysia that the transactions contemplated in the Acquisition Agreement will not result in Rowsley or its concert parties having to make a general take-over offer for remaining shares in TMCLS. The abovesaid Proposed Acquisition is expected to be completed in early 2018 and upon the completion of the Proposed Acquisition, Rowsley shall become a substantial shareholder of the Company and Mr Lim Eng Hock will still remain as a substantial shareholder of the Company by virtue of his ultimate shareholdings in Rowsley, Sasteria Pte Ltd, Sasteria (M) Pte. Ltd., Incanto Investments Limited and Best Blend Sdn. Bhd. pursuant to Section 8 of the Companies Act, 2016. This announcement is dated 20 December 2017.

icy97

林荣福扩医保业
TMC生命科学注入杰俐

2017年12月20日
（新加坡19日讯）新加坡富豪林荣福已正式把旗下的保健资产，包括在大马上市的TMC生命科学（TMCLIFE，0101，主板贸服股）的70.36%股权注入新加坡上市公司——杰俐集团（Rowsley）。

林荣福是著名的新加坡投资者，人称“股票经纪王”，也是掌控杰俐的大股东。

杰俐发文告宣布，已签署无约束投资意向书，将以19亿新元（约57.6亿令吉）收购林荣福手中的康生医疗私人有限公司（Thomson Medical）全数股权，及TMC生命科学70.36%股权，以利该集团的医疗保健业扩展计划。

根据文告，杰俐将以发售新股的方式来筹资支付这项交易，而每股发售价为7.5分（约23.50仙）。同时，集团预计可在两个月内签署正式的买卖合约。

除了收购TMC生命科学的股权，杰俐也将以现金支付方式购买该公司的5亿9731万9140张凭单。

完成上述收购后，杰俐也计划易名为康生医疗集团（Thomson Medical Group)。

冀成隆雪最大Tropicana增3倍床位

另一方面，杰俐的文告指出，TMC生命科学希望通过增加3倍床位，来让公司旗下的Tropicana医疗中心成为全巴生谷地区最大的综合医疗中心。

“当新侧楼建好后，Tropicana医疗中心将会有600张床位，并可提供最全面的第三季医疗服务。”

此外，TMC生命科学也正打算进军柔佛Vantage Bay医疗城市，打造全新的综合医疗中心——康生依斯干达（Thomson Iskandar）。

康生依斯干达占地4.139英亩，是该公司与姐妹公司新加坡康生医院合作发展。

该医疗中心将会涵括可容纳500张床的三级医院、专科医疗套房，及相关医疗和保健设备。【e南洋】

icy97

扩展Tropicana医疗中心
TMC生科颁2.6亿合约

2017年12月23日
（吉隆坡22日讯）TMC生命科学（TMCLIFE，0101，主板贸服股）宣布，颁发合约给Putra Perdana建筑私人有限公司，总值约2.6亿令吉。

TMC生命科学向交易所报备，上述合约是由子公司Tropicana医疗中心（大马）私人有限公司所颁出，以扩展Tropicana医疗中心现有的医院设备。

该公司冀望将目前的205个床位，增至635个床位，包括一栋12层楼高的医院设备，及7层楼高、共1150个停车位的建筑物。

根据文告，合约将为期31+9个月，12月将开始动工，预计会在2020年6月竣工（距离合约颁发共31个月时间）。

TMC生命科学表示，将通过内部筹资及向银行贷款，来完成上述合约。【e南洋】

Type	Announcement
Subject	OTHERS
Description	TMC LIFE SCIENCES BERHAD ("TMC" OR "THE COMPANY")- AWARD OF CONTRACT
1. INTRODUCTION The Company wishes to announce that Tropicana Medical Centre (M) Sdn. Bhd. (“TMCMSB”), a wholly owned subsidiary of the Company had on 22 December 2017 awarded the main contract for the Expansion Project to Putra Perdana Construction Sdn. Bhd. (Company No.: 158402-A) (“Contract”) for the purpose of expanding the capacity of the existing hospital facilities of Tropicana Medical Centre from the existing 205 beds to 635 beds comprising a new block of 12-storey hospital facilities and a new 7-storey block with 1,150 car parking lots. 2. SALIENT TERMS The salient terms of the Contract are as follows:- The total contract value is approximately RM260 million for a period of 31 + 9 months. The project will commence in December 2017 and is expected to be completed by June 2020 (i.e. 31 months from date of award). 3. FINANCIAL EFFECTS The Contract will not have any effect on the issued and paid-up share capital of the Company and is not expected to have any material effect on the earnings, earnings per share, net asset value and gearing of TMC Group for the financial years ending 31 August 2018, 2019 and 2020. The Contract will be funded through internally-generated funds and bank borrowing. 4. RISKS The Board of Directors of the Company does not envisage any specific risk to be associated with the Contract, apart for the operational and financial costs. 5. DIRECTORS’ AND MAJOR SHAREHOLDERS’ INTEREST None of the Directors and/or major shareholders of the Company and/or persons connected with them, have any interest, direct or indirect, in the contract. This announcement is dated 22 December 2017.

icy97

TMC LIFE SCIENCES BERHAD

EX-date	12 Feb 2018
Entitlement date	14 Feb 2018
Entitlement time	05:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final single-tier dividend of 0.167 sen per ordinary share in respect of the financial year ended 31 August 2017.
Period of interest payment	to
Financial Year End	31 Aug 2017
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200 Kuala LumpurTel:03-27839299Fax:03-27839222
Payment date	28 Feb 2018
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	14 Feb 2018
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0017

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Nov 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Nov 2017	30 Nov 2016	30 Nov 2017	30 Nov 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	41,728	36,202	41,728	36,202
2	Profit/(loss) before tax	8,324	6,105	8,324	6,105
3	Profit/(loss) for the period	6,329	4,439	6,329	4,439
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,329	4,439	6,329	4,439
5	Basic earnings/(loss) per share (Subunit)	0.36	0.26	0.36	0.26
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4200		0.4100

icy97

提高外国病人营收贡献25%
TMC生科冀并购医疗业务

2018年1月29日
（吉隆坡29日讯）TMC生命科学（TMCLIFE，0101，主板贸服股）披露，未来继续寻求收购国内外医疗相关行业，并放眼中期内，外国病人对营业额的贡献提高至25%。

TMC生命科学总执行长郭鸿盛，今日在股东大会后对媒体说，该集团一直寻求收购机会，但不会是收购土地，因为土地不会产生收入，这些潜在收购将包括国内外的医疗相关行业，而国外主要锁定东南亚区域。

“我们寻求可以产生协同效应的相关行业。”

询及TMC生命科学是否有兴趣购入太子阁医药中心（Prince Court Medical Centre）时，他说：“我们没有意思要买，因为不够吸引力。”

另外，令吉近期强势增长，惟郭鸿盛认为，这不会影响该集团的医疗旅游业务，因为我国的医疗花费，仍然比其他国家相对划算。

比较新加坡，他点出，该国的医疗花费接近我国汇率的三倍，介于3至3.1的水平，他认为来马还是有很大的成本效益。

展望2018年，他称，从各种指标来看，包括医生对病人比例及个人医疗花费，我国的医疗行业依然落后于其他国家。

不过，该集团会将盈利再投资于扩展业务，预计未来3至5年里，该集团会处于高增长阶段。

出席股东大会的还有主席拿督卡立、财务总监黄有志，及企业总监万娜蒂亚。

耗16亿拓展2医院

另一方面，郭鸿盛也汇报公司两项大型拓展计划的进展，分别是哥打白沙罗丽阳医院（TMC）以及新山康生依斯干达医院，总共耗资14亿至16亿令吉。

其中，该集团计划在3年内，耗资约1亿令吉用做丽阳医院的装备和内部装修。

此外，TMC生命科学耗资12亿令吉，在柔佛打造全新的康生依斯干达综合医疗中心，预计能在今年首季或次季取得卫生部批准。

他指出，将向银行融资30至40%，拓展康生依斯干达项目。

随着两家医院的拓展，他放眼外国病人可贡献营业额25%。

他指出，所有扩展计划的资本开销，都会通过内部融资筹集，不会进行企业活动筹资。

这是因为有母公司杰俐集团的资金支持，加上TMC生命科学本身现金充足，包括手持2亿令吉，此外，明年6月凭单活动到期时，估计也可筹得6亿5000万令吉。

不过，未来的并购活动，则不排除会通过企业活动筹资。

首季赚633万

另一方面，TMC生命科学截至去年11月30日首季，净赚632万9000令吉或每股0.36仙，年增42.58%。

首季扣除利息、税务、折旧与摊销前盈利（简称EBITDA）赚幅增长23%，推动EBITDA和净利强劲增长。去年首季EBITDA赚幅为增长18%。

首季EBITDA年增42%至940万令吉。

此外，每股净利也从0.26仙，增38%至0.36仙。

首季营业额年涨15.26%，从3620万2000令吉涨至4172万8000令吉，主要归功于病人人数增加，及处理较高难度病例。【e南洋】

icy97

Notice of Person Ceasing (Section 139 of CA 2016)

TMC LIFE SCIENCES BERHAD

Particulars of Substantial Securities Holder

Name	INCANTO INVESTMENTS LIMITED
Address	Suite 2803, 28/F One Exchange Square 8 Connaught Place, Central Hong Kong.
Company No.	1608467
Nationality/Country of incorporation	Virgin Islands, British
Descriptions (Class)	Ordinary Shares
Date of cessation	12 Apr 2018
Name & address of registered holder	UOB Kay Hian Nominees (Asing) Sdn BhdLevel 8, Symphony HousePusat Dagangan Dana 1Jalan PJU 1A/4647301 Selangor

No of securities disposed	230,000,000
Circumstances by reason of which a person ceases to be a substantial shareholder	Disposal of Shares - Pursuant to Acquisition of Sasteria Pte Ltd by Rowsley Limited on the announcement dated on 28/3/2018.
Nature of interest	Direct and Indirect Interest
Date of notice	12 Apr 2018
Date notice received by Listed Issuer	12 Apr 2018

icy97

Notice of Person Ceasing (Section 139 of CA 2016)

TMC LIFE SCIENCES BERHAD

Particulars of Substantial Securities Holder

Name	BEST BLEND SDN. BHD.
Address	157A, Jalan Sri Pelangi Taman Pelangi Johor Bahru 80400 Johor Malaysia.
Company No.	919260-X
Nationality/Country of incorporation	Malaysia
Descriptions (Class)	Ordinary Shares
Date of cessation	12 Apr 2018
Name & address of registered holder	UOB Kay Hian Nominees (Tempatan) Sdn BhdLevel 8, Symphony HousePusat Dagangan Dana 1Jalan PJU 1A/4647301 Selangor

No of securities disposed	90,000,000
Circumstances by reason of which a person ceases to be a substantial shareholder	Disposal of Shares - Pursuant to Acquisition of Sasteria Pte Ltd by Rowsley Limited on the announcement dated on 28/3/2018.
Nature of interest	Direct Interest
Date of notice	12 Apr 2018
Date notice received by Listed Issuer	12 Apr 2018

icy97

Name	SASTERIA (M) PTE LTD
Address	101 Thomson Road #14-02/03 United Square 307591 Singapore.
Company No.	201421357N
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary Shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	06 Apr 2018	90,000,000	Acquired	Direct Interest
	Name of registered holder	UOB Kay Hian Nominees (Asing) Sdn Bhd
	Address of registered holder	Level 8, Symphony House Pusat Dagangan Dana 1 Jalan PJU 1A/46 47301 Selangor
	Description of "Others" Type of Transaction
2	12 Apr 2018	230,000,000	Acquired	Direct Interest
	Name of registered holder	UOB Kay Hian Nominees (Asing) Sdn Bhd
	Address of registered holder	Level 8, Symphony House Pusat Dagangan Dana 1 Jalan PJU 1A/46 47301 Selangor
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	Acquisition of Shares - pursuant to acquisition of Sasteria Pte Ltd by Rowsley Limited on the announcement dated 28/3/2018.
Nature of interest	Direct Interest
Direct (units)	1,221,638,155
Direct (%)	70.353
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Total no of securities after change	1,221,638,155
Date of notice	12 Apr 2018
Date notice received by Listed Issuer	12 Apr 2018

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 28 Feb 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		28 Feb 2018	28 Feb 2017	28 Feb 2018	28 Feb 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	39,711	35,509	81,439	71,711
2	Profit/(loss) before tax	6,403	6,272	14,727	12,378
3	Profit/(loss) for the period	4,760	4,544	11,089	8,983
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,760	4,544	11,089	8,983
5	Basic earnings/(loss) per share (Subunit)	0.27	0.26	0.64	0.52
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4200		0.4100

icy97

icy97

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 May 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 May 2018	31 May 2017	31 May 2018	31 May 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	44,406	40,694	125,845	112,405
2	Profit/(loss) before tax	7,997	8,015	22,724	20,392
3	Profit/(loss) for the period	5,627	5,955	16,716	14,938
4	Profit/(loss) attributable to ordinary equity holders of the parent	5,627	5,955	16,716	14,938
5	Basic earnings/(loss) per share (Subunit)	0.32	0.34	0.96	0.86
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4200		0.4100

icy97

Type	Announcement
Subject	OTHERS
Description	TMC LIFE SCIENCES BERHAD ("TMC" OR "THE COMPANY")- Award of Sewerage Treatment Plant
INTRODUCTION The Company wishes to announce that BB Waterfront Sdn. Bhd. (“BBWF”), a wholly owned subsidiary of the Company had on 26 July 2018 awarded Sewerage Treatment Plant Construction and Upgrading to Dataran Tenaga Sdn Bhd. to facilitate the commencement of construction work on Thomson Iskandar Medical Hub. SCOPE OF WORK The scope of works will be a ‘design and build’ contract package which covers the following items:- To design, submit and obtain PDC-2 approval for the 42,161 P.E. underground sewage pumping station (PS), 400mm diameter D.I. pumping main and upgrading of existing oxidation pond to 63,391 P.E, fully enclosed type sewage treatment plant (STP) in 2 equal modules; To construct 375mm sewerage reticulation main; To construct, supervise, testing and commissioning of the mechanical sewerage treatment plant according the approved design; To hand over of the mechanical sewage treatment plant to Indah Water Konsortium. Contract Sum The contract sum is Ringgit Malaysia Nineteen Million Two Hundred Sixty Eight Thousand Two Hundred Seventy (RM19,268,270) only. RISKS The Board of Directors of the Company does not envisage any specific risk to be associated with the Contract, apart for the operational and financial costs. FINANCIAL EFFECTS The Contract will not have any effect on the issued and paid-up share capital of the Company and is not expected to have any material effect on the earnings, earnings per share, net asset value and gearing of TMC Group for the financial years ending 31 August 2018, 2019 and 2020. The Contract will be funded through internally-generated funds. DIRECTORS’ AND MAJOR SHAREHOLDERS’ INTEREST                                                            None of the Directors and/or major shareholders of the Company and/or persons connected with them, have any interest, direct or indirect, in the contract. This announcement is dated 26 July 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Agreement for Proposed Joint Venture
The Board of Directors of TMC Life Sciences Berhad ("the Company") wishes to inform that TMGL, the holding company has on 27 July 2018 released an announcement to Singapore Exchange pertaining to Agreement for Proposed Joint Venture, which is part of the TMGL group expansion plan. This announcement is dated 27 July 2018.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5867917

Attachments TMCLS Press Release_IVI RMA Global JV 27072018.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Unaudited Second Quarterly Financial Statement for the financial period ended 30 June 2018.
The Board of Directors of TMC Life Sciences Berhad (“The Company”) wishes to inform that Thomson Medical Group Limited (“TMGL”), the holding company of the Company had announced the unaudited second quarterly financial statement  announcement for the financial period ended 30 June 2018. Please refer to the below announcement on the website of Singapore Exchange released by TMGL: This announcement is dated 14 August 2018. http://www.bursamalaysia.com/market/listed-companies/company-announcements/5883621

Tony-Pua

第四季业绩创记录 TMC派息1.83%
Wong Ee Lin/theedgemarkets.com
October 29, 2018 19:56 pm +08

（吉隆坡29日讯）TMC生命科学（TMC Life Sciences Bhd）录得十年来最佳第四季业绩表现，净利与营业额双双创新高。

截至今年8月31日止第四季（2018财年第四季），净利按年增长2.2%至1134万令吉或每股0.65仙，2017财年第四季报1110万令吉（每股0.64仙），归功于总营运开支减少。病人及处理的病例数量增加，把营业额按年推高了9.89%，至4319万令吉。

根据彭博社数据，这是该公司在至少2008财年以来，最好的第四季营业额与净利数据。该公司于2005年在大马交易所挂牌。

该公司宣布，在截至今年8月杪财年（2018财年）派发每股1.83%或0.183仙单层终期股息，并在稍后宣布享有权益日期及付款日期。

该公司在2018财年净赚2806万令吉或每股1.62仙，比上财年的2603万令吉或每股1.5仙，按年上涨7.77%；营业额则按年上升11.42%至1亿6904万令吉，上财年为1亿5171万令吉。这是该公司连续五年获得按年净利增长。

展望未来，该公司将继续采取措施，通过引入更多服务来保持增长，同时加大宣传和营销力度，确保其成为私人患者的首选医疗保健服务供应商。

“公司在哥打白沙罗Thomson医院的扩建项目已于2018年7月完成打桩工作，建设工程正按计划进行；位于柔佛新山的Thomson Iskandar医疗中心正在获得相关监管部门的批准，预计将于2018年底开始打桩工作。”

（编译：魏素雯）

0101                 TMCLIFE                 TMC LIFE SCIENCES BHD

Quarterly rpt on consolidated results for the financial period ended 31/08/2018

Quarter: 4th Quarter Financial Year End: 31/08/2018 Report Status: Unaudited Submitted By: Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period 31/08/2018 31/08/2017 31/08/2018 31/08/2017 RM '000 RM '000 RM '000 RM '000 1 Revenue 43,194 39,307 169,039 151,712 2 Profit/Loss Before Tax 10,716 6,747 33,440 27,139 3 Profit/(loss) attributable to ordinary equity holders of the parent 11,340 11,096 28,056 26,034 4 Net Profit/Loss For The Period 11,340 11,096 28,056 26,034 5 Basic Earnings/Loss Per Shares (sen) 0.65 0.64 1.62 1.50 6 Dividend Per Share (sen) 0.18 0.17 0.18 0.17 As At End of Current Quarter As At Preceding Financial Year End 7 Net Assets Per Share (RM) 0.4300 0.4100

icy97

Type	Announcement
Subject	OTHERS
Description	Proposed Final Dividend
The Board of Directors of TMC Life Sciences Berhad is proposing a single-tier final dividend of 1.83% or 0.183 sen for the 12 months financial year ended 31 August 2018 to the shareholders for approval at the forthcoming annual general meeting. The entitlement and payment dates of the aforesaid dividend will be announced at a later date. This announcement is dated 29 October 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	TMC LIFE SCIENCES BERHAD (TMC OR THE COMPANY)-        AWARD OF CONTRACT
INTRODUCTION The Company wishes to announce that BB Waterfront Sdn. Bhd. (“BBWF”), a wholly owned subsidiary of the Company had on 31 October 2018 awarded the Piling Works to Putra Perdana Construction Sdn. Bhd. for the Proposed 33-Storey Mixed Development at PTB 24075, Jalan Stulang Darat, Stulang Laut, Bandar Johor Bahru, Daerah Johor Bahru (“the Contract”) to facilitate the construction work on Thomson Iskandar Medical Hub. CONTRACT PERIOD The Contract period will be for a period of Forty (40) weeks, commencing on 26 November 2018 and to be completed by or before 2 September 2019. CONTRACT SUM The Contract Sum is Ringgit Malaysia Forty Eight Million Six Hundred Ninety-Six Thousand Six Hundred Twenty Eight (RM48,696,628) only. RISKS The Board of Directors of the Company does not envisage any specific risk to be associated with the Contract, apart from the operational and financial costs. FINANCIAL EFFECTS The Contract will not have any effect on the issued and paid-up share capital of the Company and is not expected to have any material effect on the earnings, earnings per share, net asset value and gearing of TMC Group during the Contract period. The Contract will be funded through internally-generated funds. DIRECTORS’ AND MAJOR SHAREHOLDERS’ INTEREST None of the Directors and/or major shareholders of the Company and/or persons connected with them, have any interest, direct or indirect, in the Contract. This announcement is dated 31 October 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Unaudited Third Quarterly Financial Statement for the financial period ended 30 September 2018.
The Board of Directors of TMC Life Sciences Berhad (“The Company”) wishes to inform that Thomson Medical Group Limited (“TMGL”), the holding company of the Company had announced the unaudited third quarterly financial statement  announcement for the financial period ended 30 September 2018. Please refer to the below announcement on the website of Singapore Exchange released by TMGL: http://www.bursamalaysia.com/market/listed-companies/company-announcements/5970073 This announcement is dated 9 November 2018.